Glivec - Instructions For Use Of The Drug, Price, Reviews, Analogues

2024 Author: Rachel Wainwright | [email protected]. Last modified: 2023-12-15 07:39

Gleevec

Gleevec: instructions for use and reviews

1. 1. Release form and composition
2. 2. Pharmacodynamics and pharmacokinetics
3. 3. Indications for use
4. 4. Contraindications
5. 5. Method of application and dosage
6. 6. Side effects
7. 7. Overdose
8. 8. Special instructions
9. 9. Application during pregnancy and lactation
10. 10. Use in childhood
11. 11. In case of impaired renal function
12. 12. For violations of liver function
13. 13. Use in the elderly
14. 14. Drug interactions
15. 15. Analogs
16. 16. Terms and conditions of storage
17. 17. Terms of dispensing from pharmacies
18. 18. Reviews
19. 19. Price in pharmacies

Latin name: Glivec

ATX code: L01XE01

Active ingredient: Imatinib

Producer: Novartis Pharma (Switzerland)

Description and photo updated: 2019-30-07

Prices in pharmacies: from 63,000 rubles.

Buy

Glivec is a protein tyrosine kinase inhibitor, an antitumor agent.

Release form and composition

Dosage forms:

• Opaque capsules: size No. 3 - marked with red ink "NVR SH", from orange-yellow to light yellow, or size No. 1 - marked "NVR SI", from orange with a gray tint to orange; contents of capsules - powder, white with a yellow tinge color (size No. 3: 10 pcs. in blisters, in a cardboard box 3 blisters; size No. 1: 12 pcs. in blisters, in a cardboard box 2, 3, 4, 8, 10 or 15 blisters);
• Film-coated tablets: brownish-orange to dark yellow, biconvex, chamfered: round - labeled "NVR" on one side, "S" and "A" on the other side with dividing marks or oval - with marking on one side "400", on the other - "SL" and "SL" on both sides of the risks (10 pcs. in blisters, in a cardboard box: 100 mg - 2 or 6 blisters, 400 mg - 1 or 3 blister).

The active ingredient is imatinib mesylate:

• 1 capsule (size # 3 / size # 1) - 59.75 mg / 119.5 mg, which is equivalent to imatinib content of 50 mg / 100 mg;
• 1 tablet (round / oval) - 119.5 mg / 478 mg, which is equivalent to 100 mg / 400 mg of imatinib.

Auxiliary components:

• Capsules: titanium dioxide, microcrystalline cellulose, anhydrous colloidal silicon dioxide, crospovidone, magnesium stearate, iron dye yellow oxide, gelatin;
• Tablets: crospovidone, microcrystalline cellulose, hypromellose, magnesium stearate, colloidal silicon dioxide, macrogol 4000, yellow iron oxide, red iron oxide, talc.

Additionally, in the composition of Gleevec capsules: ink - soy lecithin, iron oxide red dye (E172), shellac.

Pharmacodynamics and pharmacokinetics

Imatinib has the following selective effects on the body:

• inhibits at the cellular level the enzyme Bcr-Abl-tyrosine kinase, which is formed by the fusion of the protooncogene Abel (Abelson) and the Bcr gene region (breakpoint cluster region);
• inhibits proliferation and induces apoptosis of Bsr-Abbl-tyrosine kinase-expressing cell lines (including immature leukemia cells that are formed in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia and chronic myeloid leukemia);
• inhibits Bcr-Abl-positive colonies, which were obtained from blood cells of patients with chronic myeloid leukemia;
• inhibits proliferation and induces apoptosis of cells of stromal neoplasms of the gastrointestinal tract, which express tyrosine kinase with a mutation of the c-Kit receptor.

The use of imatinib in the treatment of patients with metastatic and / or inoperable malignant gastrointestinal stromal neoplasms led to a significant increase in disease-free survival (21 months) and overall patient survival (48.8 months). With adjuvant therapy of gastrointestinal stromal tumors within 1 year, the risk of relapse decreased by 89%, and disease-free survival increased (placebo - 20 months, imatinib - 38 months). The result of such therapy within 3 years was a significant increase in overall survival and survival without signs of disease progression (compared with therapy lasting 1 year).

The range of Gleevec's pharmacokinetic parameters is from 25 to 1000 mg. The analysis of pharmacokinetic profiles was carried out on the 1st day, as well as when equilibrium plasma concentrations of imatinib were reached on the 7th or 28th day.

When taken orally, the bioavailability of the drug is about 98%, the variations in AUC are from 40 to 60%. In the dose range of 25–1000 mg, there is a direct linear dependence of AUC on the dose.

When comparing the intake of the drug on an empty stomach and with fatty foods, it was found that in the latter case, the following indicators slightly decrease:

• the degree of absorption (the maximum concentration of imatinib in plasma decreases by 11%, AUC - by 7.4%);
• the rate of absorption (the time to reach the maximum concentration of imatinib in plasma increases by 1.5 hours).

Plasma proteins (mainly albumin and acid alpha-glycoproteins, to a small extent - lipoproteins) bind about 95% of the drug.

Imatinib metabolism occurs mainly in the liver. The resulting major metabolite (N-demethylated piperazine derivative) circulates in the bloodstream. In vitro, the pharmacological activity of this metabolite is similar to that of the parent substance. The AUC of the metabolite is 16% of the AUC of imatinib. Plasma proteins bind the metabolite like imatinib.

The period of withdrawal from the body of one dose of Glivec is 7 days, the half-life is approximately 18 hours. The drug is excreted mainly in the form of metabolites (13% by the kidneys and 68% by the intestines). Approximately 25% of the dose is excreted unchanged (5% by the kidneys and 20% by the intestines).

Repeated administration of the drug once a day does not cause changes in pharmacokinetic parameters, and the equilibrium concentration of imatinib exceeds the initial one by 1.5–2.5 times.

In children and adolescents under the age of 18, when taken orally, the drug is rapidly absorbed by mouth. For this group of patients, the AUC indicator in the dose range of 260 and 340 mg / m2 is similar to that in adults in the dose range of 400 mg and 600 mg. When comparing the AUC values in children and adolescents on the 1st and 8th days after a repeated single dose of Gleevec at a dose of 340 mg / m2 per day, there is an increase in this indicator by 1.7 times (evidence of the cumulation of imatinib).

When Gleevec is taken by patients over 65, there is a slight increase in the volume of distribution (by 12%). For patients with a body weight of 100 kg, the average clearance of imatinib is 11.8 l / h, with a body weight of 50 kg - 8.5 l / h. These differences are insignificant, so there is no need to adjust the dose depending on body weight.

Sex differences do not affect the pharmacokinetics of imatinib. With the simultaneous administration of Gleevec and other drugs, the volume of distribution and the clearance rates of imatinib change insignificantly, so a dose change is not required.

A pooled population pharmacokinetic analysis conducted among children with hematological diseases (CML, Ph + ALL, etc.) showed that the clearance of imatinib is directly proportional to the body surface area, but other demographic parameters (BMI, body weight) do not have a clinically significant effect on its exposure., age). There is confirmed evidence that the effect of imatinib on children in the dose range of 260 or 340 mg / m2 (respectively, not higher than 400 and 600 mg) when taken 1 time per day is similar to the effect in adult patients who received imatinib at doses of 400 or 600 mg 1 once a day. In patients with varying degrees of liver function pathology, the mean AUC values do not increase.

Taking Glivec in patients with mild or moderate renal dysfunction (CC> 30 ml / min) leads to an increase in plasma imatinib exposure by 1.5–2 times, which corresponds to an increase in the concentration of acid alpha-glycoproteins. Since the drug is excreted by the kidneys to a small extent, the clearance of free imatinib in healthy volunteers and patients with pathologies of renal function is the same. No correlation was found between the severity of renal impairment and drug exposure.

Indications for use

According to the instructions, Gleevec is used to treat cancer pathologies in adult patients:

• Monotherapy for recurrent or refractory PH-positive acute lymphoblastic leukemia (ALL);
• Combination with chemotherapy for newly diagnosed Philadelphia chromosome (Ph +) ALL;
• Myeloproliferative or myelodysplastic diseases caused by gene rearrangements of the platelet growth factor receptor;
• Systemic mastocytosis with no D816V c-Kit mutation or unknown c-Kit mutation status;
• Chronic eosinophilic leukemia and / or hypereosinophilic syndrome with positive or negative abnormal FIP1L1-PDGRF alpha tyrosine kinase;
• Gastrointestinal stromal malignancies positive for c-Kit (CD 117) in the metastatic or inoperable phase;
• Bulging dermatofibrosarcoma in a metastatic, recurrent and / or inoperable stage;
• Gastrointestinal stromal tumors positive for c-Kit (CD 117) with adjuvant therapy.

In addition, Gleevec is prescribed for adults and children:

• Philadelphia chromosome (Ph +) positive chronic myeloid leukemia (CML) newly diagnosed;
• PH-positive myeloid leukemia in the chronic stage in the absence of the effect of previous treatment with interferon alpha, as well as in the phase of blast crisis or acceleration.

Contraindications

• The period of pregnancy and breastfeeding;
• Age up to 2 years;
• Hypersensitivity to drug components.

It is recommended to use Glivec with caution in case of severe renal dysfunction, regular hemodialysis, severe liver failure, cardiovascular pathologies or risk factors for the development of heart failure.

Instructions for the use of Glivek: method and dosage

Gleevec is taken orally during meals, copiously (at least 1 glass) with water.

If necessary, the contents of the capsules or tablets can be pre-dissolved in water or apple juice to form a suspension. The suspension is prepared immediately before administration in a proportion of 100 mg of Gleevec per 50 ml of liquid or 400 mg per 100 ml.

The dose and period of therapy are determined by the doctor based on clinical indications.

The drug in a dose of 400 and 600 mg is taken once a day, 800 mg is divided into 2 doses (morning and evening) of 400 mg each.

Recommended dosage:

• Chronic myeloid leukemia: chronic phase - 400 mg per day, in the phase of acceleration and blast crisis - 600 mg per day. With good tolerance and the absence of neutropenia, thrombocytopenia or other undesirable effects, an increase in the dose of up to 800 mg is shown with the progression of any stage of CML, the absence of a satisfactory hematological response after 3 months of therapy or 12 months of a cytogenetic response, and in case of loss of previously achieved hematological and / or cytogenetic indicators. For children (over 2 years old), the dose is determined based on the body surface area - 340 mg per 1 m ², but not more than 600 mg per day. The child can take the calculated dose once or in equal shares 2 times a day;
• PH-positive acute lymphoblastic leukemia: 600 mg daily;
• Myeloproliferative or myelodysplastic diseases: 400 mg per day;
• Metastatic and / or inoperable malignant stromal neoplasms of the gastrointestinal tract (GIT): 400 mg per day, with insufficient clinical effect and the absence of adverse reactions, the dose may be increased to 600 or 800 mg. In patients with signs of disease progression, Gleevec should be discontinued;
• Adjuvant therapy for gastrointestinal stromal tumors: 400 mg per day for 36 months or more;
• Bulging dermatofibrosarcoma (inoperable, recurrent and / or metastatic): 800 mg per day;
• Systemic mastocytosis in the absence of D816V c-Kit mutation: 400 mg daily. Patients with unknown mutational status and insufficient effect of previous therapy - 400 mg per day;
• Systemic mastocytosis due to abnormal FIP1L1-PDGFR alpha-tyrosine kinase against the background of fusion of the Fip like1 and PDGFR genes: initial dose - 100 mg per day, with a possible increase to 400 mg per day;
• Hypereosinophilic syndrome and / or chronic eosinophilic leukemia (HES / CEL): adult patients - 400 mg per day. In case of HES / CEL with abnormal FIP1L1-PDGFR alpha-tyrosine kinase - the initial dose of Glivec should be 100 mg per day; to increase efficiency and in the absence of severe side effects, the dose can be increased to 400 mg per day.

Gleevec is taken until the end of the clinical effect.

Patients with mild, moderate or severe liver dysfunction are prescribed Glivec in a daily dose of not more than 400 mg. With the development of toxic side effects, the dose must be reduced. Particular care should be taken when prescribing Glivek to patients with severe hepatic impairment.

In case of impaired renal function, including severe forms, or systematic hemodialysis, the initial dose of Glivec is 400 mg 1 time per day.

In patients with poor tolerance to imatinib, the initial dose can be reduced, with low efficacy, increased.

Correction of the dosage regimen for elderly patients is not required.

In the case of the development of serious non-hematological side effects while taking Gleevec, it is recommended to cancel the treatment until the symptoms of the patient's condition are eliminated.

The drug is canceled when the concentration of bilirubin increases by 3 times, the activity of hepatic transaminases in the blood serum is 5 times higher than the indicators of congenital adrenal hyperplasia (ANH). After the restoration of the concentration of bilirubin (less than 1.5 × VGN) and the activity of hepatic transaminases (less than 2.5 × VGN), the drug is resumed. The treatment is continued, reducing the initial daily dose: from 800 mg to 600 mg, from 600 mg to 400 mg, from 400 mg to 300 mg; in children - from 340 to 260 mg per 1 m ².

Temporary cancellation of therapy or dose reduction of Glivec is required when neutropenia and thrombocytopenia appear.

For systemic mastocytosis and HES / CEL (due to abnormal FIP1L1-PDGFR alpha tyrosine kinase), chronic phase of CML (adults and children), malignant stromal neoplasms of the gastrointestinal tract, myelodysplastic or myeloproliferative pathologies, systemic absolute mastocytosis and reaching a HES / HEL count of 1500 / μl and platelets more than 75,000 / μl shows the resumption of treatment in the initial dose. In the event of a repeated decrease in the number of neutrophils and platelets, after the next cancellation, treatment should be started at a dose: adults - 300 mg, children - 260 mg per 1 m ².

If the absolute number of neutrophils is less than 500 / μl and / or the number of platelets is less than 10,000 / μl in patients with PH-positive acute lymphoblastic leukemia and CML in the phase of acceleration and blast crisis (children and adults) after one or several months of therapy, it is necessary to make sure that that cytopenia is not associated with leukemia. If cytopenia is not a consequence of leukemia, the dose of Gleevec is reduced to 400 mg in adults and to 260 mg per 1 m ² in children; if cytopenia persists after 2 weeks of therapy, the dose should be reduced again to 300 mg and 200 mg per 1 m ^2, respectively. If there is no effect after 4 weeks of taking the drug, therapy is canceled until the absolute number of neutrophils is restored to more than 1000 / μl and platelets are more than 20,000 / μl. Adults start taking at a dose of 300 mg, children - 260 mg per 1 m ²…

In case of protruding dermatofibrosarcoma in an inoperable, recurrent and / or metastatic stage after discontinuation of Gleevec, treatment is resumed at a dose of 600 mg, with a repeated decrease in the number of neutrophils and / or the number of platelets - at a dose of 400 mg after recovery.

Side effects

In clinical studies of the use of Glivek in patients with inoperable and / or metastatic stromal malignant neoplasms of the gastrointestinal tract and CML, the following side effects were noted:

• Infectious pathologies: infrequently - sinusitis, herpes zoster, nasopharyngitis, herpes simplex, pneumonia, inflammation of the subcutaneous tissue, influenza, upper respiratory tract infections, gastroenteritis, sepsis, urinary tract infections; rarely - mycoses;
• Malignant, benign and unspecified tumors, including polyps and cysts: rarely - tumor lysis cider;
• Hematopoietic system: very often - thrombocytopenia, neutropenia, anemia; often - febrile neutropenia, pancytopenia; infrequently - lymphopenia, thrombocythemia, inhibition of bone marrow hematopoiesis, lymphadenopathy, eosinophilia; rarely - hemolytic anemia;
• Metabolism: often - anorexia; infrequently - impaired appetite, hypokalemia, hypophosphatemia, hyperuricemia, hyponatremia, dehydration, gout, hyperglycemia, hypercalcemia; rarely - hypomagnesemia, hyperkalemia;
• Nervous system: very often - headache; often - taste disturbance, insomnia, dizziness, hypesthesia, paresthesia; infrequently - hemorrhagic stroke, peripheral neuropathy, fainting, drowsiness, memory impairment, migraine, sciatica, tremor, restless legs syndrome, depression, decreased libido, anxiety; rarely - increased intracranial pressure, optic neuritis, convulsions, confusion;
• Senses: often - increased tearing, eyelid edema, conjunctival hemorrhage, dry eye syndrome, blurred vision, conjunctivitis; infrequently - eye pain, eye irritation, orbital edema, macular edema, retinal hemorrhages, hemorrhage in the sclera of the eye, blepharitis, tinnitus, vertigo, hearing loss; rarely - edema of the optic nerve head, cataract, glaucoma;
• Cardiovascular system: infrequently - hot flashes, palpitations, tachycardia, congestive heart failure, hemorrhage, pulmonary edema; rarely - angina pectoris, arrhythmias, decreased blood pressure, pericardial effusion, atrial fibrillation, myocardial infarction, sudden cardiac arrest, arterial hypertension, cold extremities, hematomas, Raynaud's syndrome, arterial hypotension;
• Respiratory system: often - shortness of breath, nosebleeds, cough; infrequently - pain in the pharynx or larynx, pleural effusion, pharyngitis; rarely - pulmonary fibrosis, pleural pain, pulmonary hemorrhage, pulmonary hypertension;
• Digestive system: very often - dyspepsia, nausea, vomiting, abdominal pain, diarrhea; often - dry mouth, flatulence, constipation, bloating, gastroesophageal reflux, gastritis, increased activity of liver enzymes; infrequently - belching, stomatitis, gastrointestinal bleeding, ulceration of the oral mucosa, melena, ascites, esophagitis, stomach ulcer, cheilitis, blood vomiting, pancreatitis, dysphagia, hyperbilirubinemia, hepatitis, jaundice; rarely - paralytic or obstructive intestinal obstruction, colitis, intestinal inflammation, liver necrosis, liver failure;
• Dermatological reactions: very often - skin rash, dermatitis, periorbital edema, eczema; often - dry skin, itching, facial swelling, erythema, night sweats, photosensitivity reactions, alopecia; infrequently - bruises, pustular rash, increased sweating, ecchymosis, urticaria, increased predisposition to hematoma formation, hyperpigmentation or hypopigmentation of the skin, exfoliative dermatitis, hypotrichosis, nail damage, petechiae, folliculitis, psoriasis, bullous rash, purplish; rarely - acute febrile neutrophilic dermatosis (Sweet's syndrome), discoloration of nails, angioedema, leucoclastic vasculitis, Stevens-Johnson syndrome, erythema multiforme, acute generalized pustular exanthema;
• Musculoskeletal system: very often - myalgia, arthralgia, muscle cramps and spasms, bone pain and other musculoskeletal pain; often - joint swelling; infrequently - stiffness of joints and muscles; rarely - arthritis, muscle weakness; frequency unknown - growth retardation in children;
• Urinary system: infrequently - frequent urination, hematuria, kidney pain, acute renal failure;
• Reproductive system: infrequently - erectile dysfunction, gynecomastia, menorrhagia, sexual dysfunction, menstrual irregularities, nipple pain, scrotal edema, breast enlargement;
• General reactions: very often - edema, fluid retention, weight gain, increased fatigue; often - fever, weakness, anasarca, tremors, chills, weight loss; infrequently - general malaise, chest pain;
• Laboratory indicators: infrequently - increased activity of alkaline phosphatase, creatine phosphokinase, lactate dehydrogenase and serum creatinine levels; rarely - an increase in amylase activity in blood plasma.

In addition, during additional clinical studies, adverse reactions were noted, the appearance of which was not established with the use of Gleevec:

• Cardiovascular system: infrequently - thrombosis or embolism; rarely - cardiac tamponade, pericarditis; very rarely - anaphylactic shock;
• Digestive system: infrequently - paralytic or obstructive intestinal obstruction, gastrointestinal tumor necrosis, bleeding from a gastrointestinal tumor, gastrointestinal perforation; rarely, diverticulitis;
• Respiratory system: infrequently - interstitial pneumonia, acute respiratory failure;
• Organ of vision: rarely - vitreous hemorrhage;
• Nervous system: infrequently - cerebral edema;
• Musculoskeletal system: rarely - avascular necrosis, necrosis of the femoral head, myopathy or rhabdomyolysis;
• Reproductive system: very rarely - bleeding from a cyst of the corpus luteum or ovary (in women);
• Allergic reactions: very rarely - anaphylactic shock;
• Dermatological reactions: infrequently - palmar-plantar erythrodysesthesia; rarely - lichen planus, lichenoid keratosis, toxic epidermal necrolysis.

Overdose

The experience of using Glivec in excess of therapeutic doses is limited. In clinical practice, there have been cases of drug overdose. In general, overdose cases had a favorable outcome (patients' condition improved).

Overdose symptoms in adults:

• at a dose of 1200 to 1600 mg: diarrhea, nausea, vomiting, swelling (mainly of the face), edema, erythema, rash, increased fatigue, pancytopenia, muscle spasms, thrombocytopenia, headache, abdominal pain, loss of appetite for 1– 10 days;
• at a dose from 1800 to 3200 mg (maximum daily dose for 6 days - 3200 mg): myalgia, weakness, gastrointestinal pain, increased blood levels of bilirubin and CPK;
• at a single dose of 6400 mg (according to a published source): facial edema, nausea, abdominal pain, vomiting, hyperthermia, increased activity of hepatic transaminases, a decrease in the number of neutrophils;
• at a dose from 8000 to 10000 mg: single gastrointestinal pain and vomiting.

Overdose symptoms in children and adolescents:

• in one case, anorexia, diarrhea, vomiting were noted in a 3-year-old child with a single dose of 400 mg of Glivec;
• in another case, a 3-year-old child with a single dose of 980 mg of Glivec had diarrhea and a decrease in the number of leukocytes.

Antidote to Gleevec is unknown. In case of overdose, medical supervision and symptomatic therapy are recommended.

special instructions

Avoid contact of Gleevec powder on the skin, respiratory tract, eyes.

Treatment is carried out only under the supervision of an oncologist.

Taking Glivec is recommended to be accompanied by regular clinical studies of peripheral blood, kidney and liver function, careful monitoring of patients with heart pathologies.

Due to the risk of severe fluid retention, it is necessary to control the body weight of patients, especially in elderly patients with cardiovascular diseases. If necessary, it is recommended to temporarily stop taking the drug.

Since against the background of the use of Glivec, hypothyroidism may develop in patients after thyroidectomy and are on replacement therapy with levothyroxine, the concentration of thyroid-stimulating hormone should be monitored in this category of patients.

In patients with myelodysplastic syndrome or myeloproliferative disease and high eosinophil counts, serum cardiospecific troponin and electrocardiography are examined. In case of deviations from the norm, the patient is prescribed systemic glucocorticoids simultaneously with imatinib during the first 1-2 weeks of therapy.

Careful monitoring of the state of the gastrointestinal tract is required in case of metastatic malignant gastrointestinal stromal tumor at the beginning of the use of Glivek.

During the period of treatment and at least 3 months after its termination, patients are recommended to use reliable contraception.

To reduce the risk of developing tumor lysis syndrome, elevated uric acid levels and clinically pronounced dehydration in patients should be corrected before using the drug.

When using imatinib in pediatrics, regular monitoring of the child's growth is required.

Since the drug can cause side effects that negatively affect the ability to concentrate and the speed of psychomotor reactions, the patient must be especially careful when driving vehicles and mechanisms.

Application during pregnancy and lactation

It is forbidden to take Glivec during pregnancy and lactation.

Women of childbearing age should use reliable contraceptives while taking the drug and for at least 3 months after stopping it.

Pediatric use

The experience of treating chronic myeloid leukemia in children under 3 years of age is limited.

Glivec is not prescribed for children under 2 years of age.

The recommended dose for children over 2 years of age depends on the surface area of the body. The drug in a daily dose of 340 mg / m2 is used in the treatment of children with a chronic phase of chronic myeloid leukemia and an acceleration phase. The maximum daily dose for children is 600 mg.

With impaired renal function

The kidneys have no significant effect on the elimination of imatinib and its metabolites. Therapy of patients with mild or moderate pathologies of renal function should be started with a minimum effective daily dose of 400 mg once. The experience of using Gleevec when carrying out a regular hemodialysis procedure or treating patients with severe pathologies of renal function is limited, but for this category of patients, drug therapy should also begin with 400 mg of the drug once a day.

For patients with severe pathologies of renal function, the drug is prescribed with caution.

For violations of liver function

Since the metabolism of imatinib occurs mainly in the liver, patients with liver function pathologies of any severity are recommended to prescribe a minimum daily dose of Gleevec - 400 mg. If undesirable toxic effects appear, the dose of the drug should be reduced.

The drug is prescribed with caution in patients with severe hepatic impairment.

Use in the elderly

When treating this category of patients, dose adjustment is not required.

Drug interactions

The possibility of simultaneously taking other drugs during the treatment with Glivec can only be determined by the oncologist individually.

Analogs

Analogs of the Gleevec drug are: Nexavar, Afinitor, Sprysel, Votrient, Sutent, Taiverb, Tasigna, Tarceva, Ksalkori, Inlita, Jakavi, Kaprelsa, Rafinlar, Zelboraf, Giotrif, Bosulif, Mekinist, Imbruvika, Tarinibimatyeva, Tarlenibieva Medak, Gemfatinib, Filachromin FS, Imagliv, Neopax, Imatib, Gistamel.

Terms and conditions of storage

Store at temperatures up to 30 ° C. Keep out of the reach of children.

The shelf life is 3 years.

Terms of dispensing from pharmacies

Dispensed by prescription.

Reviews about Gleevec

The few reviews about Gleevec are, as a rule, positive. According to the patients taking the drug or relatives of such patients, treatment can significantly alleviate the symptoms of the disease being observed.

However, it should be noted that almost all patients undergoing drug therapy experienced some side effects, which in some cases became the reason for a dose reduction or complete cessation of treatment.

Price for Gleevec in pharmacies

The price of Glivec 100 mg (60 tablets per pack) is about 35,000 rubles, Glivec 400 mg (30 tablets per pack) - about 56,000 rubles, Glivec 100 mg (120 capsules per pack) - about 74,000 rubles.

Gleevec: prices in online pharmacies

Drug name Price Pharmacy

Glivec 100 mg capsule 120 pcs. RUB 63,000 Buy

Anna Kozlova Medical journalist About the author

Education: Rostov State Medical University, specialty "General Medicine".

Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!